Guatemala's modernized clinical research framework — anchored by Ministerial Agreement 206-2021 and ISO 14155 alignment — makes it one of Central America's most credible destinations for first-in-human medical device studies. With a National Health Ethics Committee (Comité Nacional de Ética en Salud) that targets a 45-business-day review (subject to clock pauses), a Guatemala City medical hub, and bioaccess®'s regulatory coordination, sponsors reach patients faster and at ~30% lower cost than US/EU programs.
Guatemala is the largest economy in Central America and has invested significantly in modernizing its clinical research regulatory framework. Since October 30, 2021, human clinical trials have been governed by Ministerial Agreement 206-2021, which is explicitly aligned with ISO 14155 and the Declaration of Helsinki. This gives sponsors a clear, defensible pathway for generating FDA-quality first-in-human data.
The Ministry of Public Health and Social Assistance (MSPAS), through its Department of Regulation and Control of Pharmaceutical and Related Products, serves as the national regulatory authority. Ethics oversight is centralized in a National Health Ethics Committee (Comité Nacional de Ética en Salud) based in Guatemala City, which meets weekly and has a statutory review target of 45 business days, subject to clock pauses for agency queries — providing a more predictable framework than many larger LATAM markets, though not a guaranteed total start-up time.
Guatemala City anchors the country's medical infrastructure, with hospitals and investigators experienced in international clinical work. bioaccess® manages the complete regulatory pathway — MSPAS submissions in Spanish and English, ethics coordination, site qualification, and monitoring — so sponsors get FDA-submissible data at roughly 30% lower cost than a comparable US or EU program.
Since October 30, 2021, clinical trials in Guatemala have been governed by Ministerial Agreement 206-2021, which aligns national requirements with ISO 14155 and the Declaration of Helsinki. The Ministry of Public Health and Social Assistance (MSPAS), through its Department of Regulation and Control of Pharmaceutical and Related Products, is the competent authority for authorizing clinical investigations. bioaccess® prepares complete regulatory dossiers for MSPAS submission.
Ethics oversight for clinical research in Guatemala is coordinated through a National Health Ethics Committee (Comité Nacional de Ética en Salud) based in Guatemala City. The committee meets weekly and has a statutory review target of 45 business days, subject to clock pauses for agency queries (RFIs) — a predictable framework, not a guaranteed total start-up time. Documents are submitted in Spanish and English. bioaccess® manages the ethics package end-to-end, including protocol, informed consent, investigator brochure, and insurance documentation.
Guatemala City is the medical hub of Central America's largest economy, with hospitals, imaging capabilities, and investigators experienced in ISO 14155-aligned research. bioaccess® qualifies sites, trains site personnel on protocol-specific procedures, and provides on-the-ground monitoring so sponsors get consistent, source-verified data across the study.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Guatemala for IDE submissions and marketing applications, provided studies are conducted under ISO 14155 with proper MSPAS authorization and ethics approval. bioaccess® designs every protocol for FDA submission from day one — with source data verification, monitoring plans, and documentation practices built around 21 CFR expectations.
| Metric | Guatemala 🇬🇹 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory framework | Ministerial Agreement 206-2021 (ISO 14155) | 21 CFR 812 (IDE + IRB) | EU CTR / MDR + per-country EC |
| Ethics committee response | 45-business-day target (clock pauses apply) | IRB varies | 3–6 months |
| Regulatory authority | MSPAS — Dept. of Pharma & Related Products | FDA | EMA / national CAs |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Time zone vs. US | Central (CST) | Same/near | +6 to +9 hours |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The Ministry of Public Health and Social Assistance (MSPAS), through its Department of Regulation and Control of Pharmaceutical and Related Products, is Guatemala's national regulatory authority for clinical investigations under Ministerial Agreement 206-2021.
Human clinical trials in Guatemala are governed by Ministerial Agreement 206-2021, in force since October 30, 2021, which follows ISO 14155 and the Declaration of Helsinki.
The National Health Ethics Committee (Comité Nacional de Ética en Salud), based in Guatemala City, meets weekly and has a statutory review target of 45 business days from submission, subject to clock pauses for agency queries — not a guaranteed total start-up time. Documents are submitted in Spanish and English.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Guatemala when studies are conducted under ISO 14155 with proper MSPAS authorization and ethics approval. bioaccess® designs protocols for FDA submission from the start.
Guatemala programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Guatemala combines a modernized 2021 regulatory framework, a predictable 45-business-day ethics response, ISO 14155 alignment, and the medical infrastructure of Central America's largest economy. It's a strong single-country choice or a valuable addition to a multi-country LATAM strategy.
All countries we serve · Contact bioaccess® · First-in-Human CRO